|Day Low/High||183.70 / 186.56|
|52 Wk Low/High||142.81 / 197.00|
- Allergan Hosting Analyst Event at the 2018 AAO Annual Meeting Including Conference Call and Webcast on Friday, October 26, at 6:30 p.m. Central Time (7:30 p.m. Eastern Time) -
--One-year study continues to support positive safety and tolerability profile for ubrogepant--
DUBLIN and SAN FRANCISCO, Oct. 16, 2018 /PRNewswire/ -- Allergan plc (NYSE:AGN), a leading global pharmaceutical company, and Medicines360, a global nonprofit women's health pharmaceutical company with a mission of expanding access to quality medicines,...
DUBLIN, Oct. 11, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company, announced today that it will present 13 abstracts at the annual American Society for Dermatologic Surgery (ASDS) meeting in Phoenix, AZ from October...
DUBLIN, Oct. 8, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced it will present data from its gastroenterology portfolio at the American College of Gastroenterology Annual Scientific Meeting (ACG),...
- New programs will evaluate the safety and efficacy of brazikumab (an investigational drug) and the potential correlation between biomarkers and patient outcomes with brazikumab
DUBLIN, Oct. 4, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced that the CoolSculpting ® treatment received FDA clearance to treat the submandibular area.
Aegon's subsidiary Transamerica today announces an agreement that would resolve litigation challenging certain monthly deduction rate adjustments on universal life insurance policies in the United States.
Bigger, bolder JUVÉDERM® campaign seeks to make JUVÉDERM® a household name for consumers
DUBLIN, Oct. 1, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced that it intends to release third quarter 2018 financial results on Tuesday, October 30, 2018, prior to the open of U.
Straying from these names could land you in quicksand as the 4th quarter begins.
Allergan Foundation pledges $2,000,000 to support breast health research
- Application Seeks to Expand VRAYLAR Indication to Include the Treatment of Bipolar Depression -
Aegon expects a one-time benefit to capital generation of approximately USD 1 billion as a result of the merger of two legal entities.
The company and actor join forces to pay homage to those affected by Alzheimer's Disease
Aegon will repurchase 24,133,950 common shares to neutralize the dilutive effect of the 2018 interim stock dividend.
- Study met primary endpoint demonstrating that higher doses of BOTOX® Cosmetic produce greater duration of treatment effect -
-- Allergan Medical Aesthetics Business Has Potential to Double by 2025 Driven by Consumer Trends, Geographic Expansion and Innovation --
- Acquisition Adds Fast-Acting Neurotoxin Programs with 2 to 4-Week Duration to Allergan's Best-in-Class Medical Aesthetics Portfolio and Pipeline -
Spotlyte marks the first launch from Allergan digital ventures unit, Project Moonwalker™
DUBLIN, Sept. 10, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced that it will host a Medical Aesthetics Day event and webcast on Friday, September 14, 2018.
NOVEL, DUAL-ACTING PRODUCT REVITALIZES AND PROTECTS SKIN AGAINST BLUE LIGHT AND ENVIRONMENTAL AGRESSORS AROUND THE CLOCK
The entrance of more competition for Botox Cosmetic could expand the market, the drugmaker's top executive says at the Wells Fargo Healthcare Conference in Boston.
DUBLIN, Sept. 4, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global biopharmaceutical company, today announced that Chairman and CEO Brent Saunders will participate in a fireside chat at the 2018 Morgan Stanley Global Healthcare Conference in...
DUBLIN, Aug. 30, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global biopharmaceutical company, today announced that Chairman and CEO Brent Saunders will participate in a fireside chat at the 2018 Wells Fargo Healthcare Conference in Boston,...
-- Director Paul Bisaro to Retire from Allergan Board --
Today, US subsidiaries of Aegon reached a settlement with the Securities and Exchange Commission (SEC) in the matter of the operation and implementation of asset management quantitative models by Aegon's US asset management operations, and related...
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.